These 2 Top Dividend Stocks Are Finally Rebounding, and There Might Be More Upside Ahead

Key Points

• Apple may be setting up a robust renewal cycle that will strengthen its vast ecosystem.

• Eli Lilly is expected to secure several key approvals in the next few years.

• Both companies have significant upside and offer robust dividend programs.

• 10 stocks we like better than Apple ›

Apple (NASDAQ: AAPL) and Eli Lilly (NYSE: LLY) have faced significant volatility this year. However, both companies have benefited from recent positive developments, and their shares surged over the past month or so.

Here's some even better news for investors: There could be plenty of upside left for these market leaders. Apple and Eli Lilly are top picks for both growth-oriented and income-seeking investors.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

Image source: Getty Images.

1. Apple

Apple has faced several issues this year. First, while its tech peers are benefiting from their work in artificial intelligence (AI), the iPhone maker's initiatives in this field haven't been as impressive as some would have liked, and definitely not on par with those of its similarly-sized competitors. Second, heavy tariffs on imported goods -- especially from China, where Apple manufactures a significant portion of its products -- could erode its margins and bottom line.

Even so, Apple rebounded over the past few months, partly thanks to efforts to appease the Trump administration and avoid extremely punitive tariffs. More recently, during its latest event, the company announced its lineup of new products. There was nothing groundbreaking related to AI, but some analysts believe Apple's new iPhone 17 line could once again kick-start a strong renewal cycle.

Given all that's happening, the stock has risen by 17% over the past six months, and I think it remains attractive for long-term investors.

Apple's most recent results, for the third quarter of its fiscal year 2025 (ended June 28), were strong and continued to show momentum in a key category: active devices. Revenue increased 10% year over year to $94 billion, earnings per share rose 12% to $1.57 compared to the year-ago period, and active devices reached new all-time highs across all categories.

With more than 2 billion devices in circulation -- and more than 1 billion paid subscriptions -- Apple's services segment is slowly but surely growing. The segment's juicier margins will, in the long run, help the company significantly improve its bottom line, provided it maintains or grows its installed base. Apple's recent quarterly update, along with expectations for the newest iPhones and other devices, demonstrates that it's capable of doing so.

Lastly, the stock is a terrific pick for dividend seekers. True, it has an unimpressive forward yield of around 0.4%. However, Apple generates a substantial amount of free cash flow, has increased its dividends by 100% over the past decade, and boasts a highly conservative payout ratio of 16%, which leaves ample room for further dividend increases. Apple can still deliver market-beating returns over the long run while consistently growing its dividend.

2. Eli Lilly

Eli Lilly's shares dropped Aug. 7 after it reported mixed phase 3 results for its investigational oral GLP-1 candidate, orforglipron. The medicine induced a mean weight loss of 12.4% in overweight or obese (but not diabetic) patients over 72 weeks. Wall Street was hoping for better weight-loss numbers, and lower rates of clinical-trial dropouts due to adverse reactions. However, following that debacle, the company has performed well: The stock is up 15% since.

One reason Lilly is rebounding is that it reported data from another phase 3 study for orforglipron, this time in overweight or obese and diabetic patients. The medicine's weight loss numbers and A1C reductions in this study were significant, positioning it for regulatory submissions. The therapy also proved more effective than Novo Nordisk's oral GLP-1 drug, Rybelsus, in a head-to-head study.

Eli Lilly is already a dominant player in the weight loss market. The approval of orforglipron -- likely by early 2027 at the latest -- should cement the company's status in the field.

In the meantime, expect to see further pipeline progress for the drugmaker. Its candidate retatrutide looks perhaps even more promising than its current crown jewel, Zepbound. Retatrutide induced weight loss of up to 24.2% in 48 weeks at the highest dose in a phase 2 study, with weight still falling afterwards, while Zepbound had a mean weight loss of up to 22.5% after 72 weeks. Retatrutide still needs to complete phase 3 results, but things are looking promising.

With these upcoming new launches, Lilly should maintain strong sales and earnings growth for the foreseeable future. The drugmaker's second-quarter revenue was up 38% year over year to $15.6 billion, an outstanding performance for a pharmaceutical company of this size.

Lastly, there's the dividend, which has increased by 200% in the past decade. The company's payout ratio of about 44% looks reasonable. The forward yield is a modest 0.8%, but Eli Lilly's strong underlying business and willingness to grow its payouts more than compensate for that.

Should you invest $1,000 in Apple right now?

Before you buy stock in Apple, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Apple wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $652,872!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,092,280!*

Now, it’s worth noting Stock Advisor’s total average return is 1,062% — a market-crushing outperformance compared to 189% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of September 29, 2025

Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Apple. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.